# Study of E7389 for Advanced or Metastatic Breast Cancer

> **NCT00965523** · PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 81 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Eribulin Mesylate

## Key facts

- **NCT ID:** NCT00965523
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-12
- **Final completion:** 2011-01
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2013-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00965523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00965523, "Study of E7389 for Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00965523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*